Hyun Sub Cheong1, Youngil Koh, Kwang-Sung Ahn, Chansu Lee, Hyoung Doo Shin, Sung-Soo Yoon. 1. aCancer Research Institute bDepartment of Internal Medicine, Seoul National University College of Medicine cClinical Research Institute, Seoul National University Hospital dDepartment of Genetic Epidemiology, SNP Genetics Inc. eFunctional Genome Institute, PDXen Biosystem Inc. fDepartment of Life Science, Sogang University, Seoul, Korea.
Abstract
AIMS: The cytosolic 5'-nucleotidase-III (NT5C3) is involved in the metabolism of the nucleoside analog, cytosine arabinose (AraC), and the expression level of NT5C3 is correlated with sensitivity to AraC in acute myeloid leukemia (AML) patients. The current study examined whether the NT5C3 polymorphisms could affect chemotherapy outcomes in 103 Korean AML patients. METHODS: Forty-seven single nucleotide polymorphisms in NT5C3 were genotyped using the Illumina GoldenGate genotyping assay. The genetic effects of the polymorphisms on the outcome of chemotherapy were analyzed using χ and logistic regression models. RESULTS: Although none of the NT5C3 polymorphisms was associated with a complete remission rate, a common single nucleotide polymorphism, rs3750117, showed a significant association with induction rate after the first course of chemotherapy (Pcorr=0.004 and odds ratio=11.28) in AML patients. In addition, NT5C3 expression levels were significantly increased in patients with risk allele homozygote. CONCLUSIONS: The data suggest that genotyping the NT5C3 polymorphism may have the potential to identify patients more likely to respond to AraC-based chemotherapy.
AIMS: The cytosolic 5'-nucleotidase-III (NT5C3) is involved in the metabolism of the nucleoside analog, cytosine arabinose (AraC), and the expression level of NT5C3 is correlated with sensitivity to AraC in acute myeloid leukemia (AML) patients. The current study examined whether the NT5C3 polymorphisms could affect chemotherapy outcomes in 103 Korean AMLpatients. METHODS: Forty-seven single nucleotide polymorphisms in NT5C3 were genotyped using the Illumina GoldenGate genotyping assay. The genetic effects of the polymorphisms on the outcome of chemotherapy were analyzed using χ and logistic regression models. RESULTS: Although none of the NT5C3 polymorphisms was associated with a complete remission rate, a common single nucleotide polymorphism, rs3750117, showed a significant association with induction rate after the first course of chemotherapy (Pcorr=0.004 and odds ratio=11.28) in AMLpatients. In addition, NT5C3 expression levels were significantly increased in patients with risk allele homozygote. CONCLUSIONS: The data suggest that genotyping the NT5C3 polymorphism may have the potential to identify patients more likely to respond to AraC-based chemotherapy.
Authors: Abdelrahman H Elsayed; Xueyuan Cao; Kristine R Crews; Varsha Gandhi; William Plunkett; Jeffrey E Rubnitz; Raul C Ribeiro; Stanley B Pounds; Jatinder K Lamba Journal: Pharmacogenomics Date: 2018-08-08 Impact factor: 2.533
Authors: Taynah Cascaes Puty; Jonathan Souza Sarraf; Tabata Cristina Do Carmo Almeida; Valter Cordeiro Barbosa Filho; Luis Eduardo Werneck de Carvalho; Fernando Luiz Affonso Fonseca; Fernando Adami Journal: Syst Rev Date: 2019-05-03